Ranadive Sayali A, Ersoy Baran, Favre Helene, Cheung Clement C, Rosenthal Stephen M, Miller Walter L, Vaisse Christian
Department of Pediatrics, Division of Endocrinology, University of California San Francisco, San Francisco, CA 94143, USA.
Clin Endocrinol (Oxf). 2009 Sep;71(3):388-93. doi: 10.1111/j.1365-2265.2008.03513.x. Epub 2008 Dec 18.
X-linked nephrogenic diabetes insipidus (XNDI), caused by mutations in the V2 vasopressin receptor (V2R), is clinically distinguished from central diabetes insipidus (CDI) by elevated serum vasopressin (AVP) levels and unresponsiveness to 1-desamino-8-d-arginine vasopressin (DDAVP). We report two infants with XNDI, and present the characterization and functional rescue of a novel V2R mutation.
Two male infants presented with poor growth and hypernatraemia. Both patients had measurable pretreatment serum AVP and polyuria that did not respond to DDAVP, suggesting NDI. However, both also had absent posterior pituitary bright spot on MRI, which is a finding more typical of CDI.
The AVPR2 gene encoding V2R was sequenced. The identified novel missense mutation was re-created by site-directed mutagenesis and expressed in HEK293 cells. V2R activity was assessed by the ability of transfected cells to produce cAMP in response to stimulation with DDAVP. Membrane localization of V2R was assessed by fluorescence microscopy.
Patient 1 had a deletion of AVPR2; patient 2 had the novel mutation L57R. In transiently transfected HEK293 cells, DDAVP induced detectable but severely impaired L57R V2R activity compared to cells expressing wild-type V2R. Fluorescence microscopy showed that myc-tagged wild-type V2R localized to the cell membrane while L57R V2R remained intracellular. A nonpeptide V2R chaperone, SR121463, partially rescued L57R V2R function by allowing it to reach the cell membrane.
L57R V2R has impaired in vitro activity that can be partially improved by treatment with a V2R chaperone. The posterior pituitary hyperintensity may be absent in infants with XNDI.
X连锁肾性尿崩症(XNDI)由血管加压素V2受体(V2R)突变引起,临床上与中枢性尿崩症(CDI)的区别在于血清血管加压素(AVP)水平升高以及对1-去氨基-8-D-精氨酸血管加压素(DDAVP)无反应。我们报告了两名XNDI婴儿,并介绍了一种新型V2R突变的特征及功能挽救情况。
两名男婴出现生长发育迟缓及高钠血症。两名患者治疗前血清AVP均可测,且存在对DDAVP无反应的多尿症状,提示为尿崩症。然而,两人MRI检查均显示垂体后叶亮点缺失,这一表现更常见于CDI。
对编码V2R的AVPR2基因进行测序。通过定点诱变重新构建鉴定出的新型错义突变,并在HEK293细胞中表达。通过转染细胞对DDAVP刺激产生环磷酸腺苷(cAMP)的能力评估V2R活性。通过荧光显微镜评估V2R的膜定位。
患者1存在AVPR2缺失;患者2有新型突变L57R。在瞬时转染的HEK293细胞中,与表达野生型V2R的细胞相比,DDAVP诱导可检测到但严重受损的L57R V2R活性。荧光显微镜显示,带有myc标签的野生型V2R定位于细胞膜,而L57R V2R仍保留在细胞内。一种非肽类V2R伴侣分子SR121463通过使L57R V2R到达细胞膜,部分挽救了其功能。
L57R V2R体外活性受损,用V2R伴侣分子治疗可部分改善。XNDI婴儿可能不存在垂体后叶高强度信号。